In an interview, the US pharmaceuticals giant’s international chief says Australia has made no progress in making life easier for medicine developers.

MICHAEL BECKLEY is Associate Professor of Political Science at Tufts University, a Nonresident Senior Fellow at the American ...

Pfizer PFE announced that it is discontinuing the development of danuglipron, its investigational oral GLP-1 receptor agonist (GLP-1 RA), which is being developed to treat obesity. The decision ...

A new study explores how financial and non-financial actors shape food system investments in Australia, revealing who holds ...

The percentage of U.S. adults diagnosed with obesity using BMI is similar to those defined as having excess adiposity. Researchers said confirming excess adiposity in people with obesity may not ...

When it comes to managing weight loss and type 2 diabetes with medications, research shows that it's out with the old and in with the new. The rate of emergency department visits for adverse ...

Pfizer is ending the development of its potential once-daily pill treatment for obesity before venturing into the biggest and most expensive level of clinical testing. The drugmaker said Tuesday ...

The company has really been under the watch of investors for some time, and you can see on your screen the struggle that it had to really enter this obesity space already, ending one candidate ...

Lilly said it would seek approval from the Food and Drug Administration later this year to market orforglipron for obesity and early in 2026 for diabetes. Industry analysts expect the drug to win ...

A new generation of obesity drugs is transforming patients’ lives, dividing medical experts, and spurring the biggest business battle in years. Known as GLP-1-based drugs, this medication class ...